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Background. Respiratory infections are a major cause of asthma exacerbations where neutrophilic inflammation dominates and
is associated with steroid refractory asthma. Structural airway cells in asthma differ from nonasthmatics; however it is unknown
if neutrophils differ. We investigated neutrophil immune responses in patients who have good (AGood) and suboptimal (ASubopt)
asthma symptom control. Methods. Peripheral blood neutrophils from AGood (ACQ < 0.75, 𝑛 = 11), ASubopt (ACQ > 0.75, 𝑛 = 7),
and healthy controls (HC) (𝑛 = 9) were stimulatedwith bacterial (LPS (1𝜇g/mL), fMLF (100 nM)), and viral (imiquimod (3𝜇g/mL),
R848 (1.5𝜇g/mL), and poly I:C (10 𝜇g/mL)) surrogates or live rhinovirus (RV) 16 (MOI1). Cell-free supernatant was collected after
1 h for neutrophil elastase (NE) and matrix metalloproteinase- (MMP-) 9 measurements or after 24 h for CXCL8 release. Results.
Constitutive NE was enhanced in AGood neutrophils compared to HC. fMLF stimulated neutrophils from ASubopt but not AGood
produced 50%ofHC levels. fMLF inducedMMP-9was impaired inASubopt andAGood compared toHC. fMLF stimulatedCXCL8 but
notMMP-9was positively correlatedwith FEV
1
and FEV
1
/FVC.ASubopt andAGood responded similarly to other stimuli.Conclusions.
Circulating neutrophils are different in asthma; however, this is likely to be related to airflow limitation rather than asthma control.
1. Introduction
Mainstay therapy for asthma is a combination of a long-acting
𝛽
2
agonist to relax smooth muscle in the airways and a corti-
costeroid to reduce inflammation in the lungs [1]. However,
even at high doses of these medications some patients remain
unresponsive. These patients with uncontrolled or difficult
to treat asthma often have a neutrophilic phenotype [2, 3];
however a group of patients with a steroid refractory eosin-
ophilic phenotype also exist [4, 5].These patients not only are
unable to obtain symptom relief but also suffer from more
frequent and severe exacerbations [6, 7].
Asthma exacerbations may be triggered by a number
of provokers of which the most common are respiratory
infections. Viral infections have been extensively studied and
rhinovirus (RV) is the most commonly detected virus in
exacerbating adults [8]. Bacterial infections are not as rigor-
ously examined but appear to also be clinically significant [9].
Respiratory infections pose a high threat to patients suffering
from uncontrolled asthma as they can trigger exacerbations
that are often severe and leave the patient hospitalised with
limited treatment options [10, 11].
Neutrophils are the most abundant immune cell in the
body; their main effector role is to control infections. CXCL8
is a potent neutrophil chemoattractant, neutrophil elastase
(NE) has potent antimicrobial properties, and matrix metal-
loproteinase- (MMP-) 9 is important in activating antimi-
crobial peptides, all of which are released by neutrophils.
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Table 1: Patient characteristics of healthy controls and asthmatics.
Healthy controls Asthma, well-controlled Asthma, suboptimally controlled
𝑁 9 11 7
Age years, mean (±SEM) 60.22 (±5.12) 62.64 (±3.97) 62.57 (±4.02)
Gender (M/F) 6/3 7/4 5/2
ACQ, mean (±SEM) 0 (±0) 0.32 (±0.08)∗ 1.33 (±0.17)∗∗∗∗/####
FEV
1
% pred. (±SEM) 92.78 (±5.98) 80.55 (±7.71) 70.29 (±8.09)
FEV
1
/FVC% pred. (±SEM) 101.8 (±1.65) 88.36 (±4.51)∗ 77.43 (±5.27)∗∗
Short-acting 𝛽
2
agonist use (Y/N) 0/9 9/0 7/0
∗
𝑝 < 0.05, ∗∗𝑝 < 0.01, and ∗∗∗∗𝑝 < 0.0001 compared to healthy controls.
####
𝑝 < 0.0001 compared to patients with asthma with good symptom control.
ACQ: asthma control questionnaire.
FEV1: forced expiratory volume in 1 second.
FVC: forced vital capacity.
Transient neutrophilia and neutrophilic inflammation are a
normal phase of the immune response to pathogens [12];
however, chronic airway inflammation occurs in stable
asthma [2, 13, 14]. In a study of 205 patients, multivariate lin-
ear regression has shown no association of airway neu-
trophilia with corticosteroid use [15], and airway neutrophilia
occurs in asthmatic patientswho are corticosteroid naı¨ve [16].
In addition, neutrophil numbers [2] and neutrophil inflam-
matory mediators such as CXCL8 [17], NE [18], and MMP-9
[19] are elevated in the airways of patients with severe asthma
and these levels correlate with disease severity [2, 20].
It has been shown that structural cells, such as epithelial
and smoothmuscle cells, in the asthmatic airway are different
compared to nonasthmatic cells in both morphology and
function [21–24]. It is believed that these functional abnor-
malities drive other changes in the airways which give rise to
the hallmarks of asthma.Wepreviously found that circulating
neutrophils from patients with asthma are altered in their
response to the viral mimetic, R848 by producing elevated
levels of CXCL8 [25], and expression quantitative trait loci
mapping in neutrophils has found immune dysfunction trait
associated variants [26]. However, to date it has not been
investigated if neutrophil functions differ in patients with
suboptimal symptom control despite takingmoderate to high
dose steroid therapy. Neutrophil dysfunction may occur in
these patients which would, in part, account for the greater
inflammatory mediator load in this group of patients.
Neutrophils are produced in the bone marrow and have a
relatively short life span [27, 28]. Given our previous finding
of different responses of lung versus circulating neutrophils
[29], to ascertain if neutrophils are already different prior
to entering the lung in well- and suboptimally controlled
asthma we compared the response to both bacterial and viral
mimetics in circulating neutrophils to avoid any potential
confounding effects of the lung inflammatory environment.
We hypothesised that neutrophils from patients with subop-
timally controlled asthma have a defective innate immunity
which may predispose to pathogen-induced exacerbations.
2. Materials and Methods
2.1. Volunteer Recruitment. The project was approved by
the Human Research Ethics Committee, The University of
Sydney, prior to commencement. Volunteers with doctor
diagnosed asthma, stable disease, and no reported symp-
toms of respiratory infection were recruited into the study.
Healthy control volunteers were also recruited. Participants
were required to be over 18 years of age and be fluent in
English. Exclusion criteria included if they were pregnant,
were known to faint during venipuncture procedures, or had
a blood borne infection or condition. All volunteers provided
written informed consent and were asked to complete a
standardised questionnaire regarding age, gender, asthma
symptoms, asthma medication use, and smoking history.
Patients also completed baseline spirometry for forced expi-
ratory volume in 1 second (FEV
1
) and forced vital capacity
(FVC). Participants with asthmawere asked to withhold their
short-acting 𝛽
2
agonists for a minimum of 6 hours and 24
hours for long-acting 𝛽
2
agonists and inhaled corticosteroids
(ICS).
2.2. Categorisation of Asthmatics. Participants with asthma
were stratified based on their asthma control questionnaire
(ACQ) score [30]. A cut point of ACQ < 0.75 was used
to identify well-controlled asthma [30]. Participants with
suboptimal asthma control (ACQ ≥ 0.75) also had evidence
of variable airflow limitation (PD
15
< 15mL hypertonic saline
or standard challenge agent, change in postbronchodilator
FEV
1
> 12% of 200mL, >12% peak flow variability over at
least 1 week, or FEV
1
variability >12% of two measurements
within two months of each other) and were taking a min-
imum of GINA step 3 maintenance combination therapy.
Patient information is provided in Tables 1 and 2.
2.3. Neutrophil Isolation. Neutrophils were isolated from
peripheral blood collected from volunteers with and with-
out asthma by a modified standard protocol [29, 31, 32].
Briefly, 40mL of blood was mixed with 10mL acid citrate
dextrose (ACD), 10mL of phosphate buffered saline (PBS)
(Gibco, Carlsbad, CA, USA), and 6mL of 10% dextran (MP
Biomedicals, Santa Ana, USA) and left for 20 minutes for
sedimentation to occur at room temperature. The top layer
was removed, overlaid on Ficoll Paque-PLUS (GEHealthcare,
Little Chalfont, UK), and centrifuged at 490 g for 10 minutes.
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Table 2: Smoking history and inhaled corticosteroid (ICS) use of healthy controls and asthmatics.
(a)
Healthy controls
Age Sex Smoking status Pack years
66 Male Nonsmoker 0
66 Male Nonsmoker 0
62 Female Ex-smoker 15
70 Male Nonsmoker 0
63 Female Nonsmoker 0
67 Male Nonsmoker 0
61 Female Nonsmoker 0
67 Male Nonsmoker 0
20 Male Nonsmoker 0
(b)
Asthma, well-controlled∗
Age Sex Smoking status Pack years Daily ICS BDP-HFAequivalent (𝜇g/day) ICS in last 12 months in BDP-HFA equivalent (𝜇g/day)
69 Female Nonsmoker 0 0 200 (during exacerbations)
71 Male Ex-smoker 18 200 —
75 Male Nonsmoker 0 0 —
63 Male Ex-smoker 0.5 1000 2000 (when needed)
52 Male Nonsmoker 0 0 200† (exercise only)
61 Female Nonsmoker 0 0 200 (in the last 12months, ceased 3months ago)
63 Male Current smoker 43 0 200 (in high humidity, not used in the past months)
73 Male Ex-smoker 21 1000 —
28 Male Nonsmoker 0 125 —
69 Female Nonsmoker 0 100† 200† (when sick)
65 Female Nonsmoker 0 250 500 (when sick)
(c)
Asthma, suboptimally controlled∗
Age Sex Smoking status Pack years Daily ICS BDP-HFA equivalent (𝜇g/day) Oral steroid use in last 12 months
62 Male Ex-smoker 0.2 800 Yes
71 Female Ex-smoker 0.6 400 Yes
74 Male Ex-smoker 4.5 1000 No
47 Male Nonsmoker 0 1000 No
73 Female Nonsmoker 0 1000 Yes
52 Male Ex-smoker 7.15 200 No
59 Male Nonsmoker 0 500 No
∗See Section 2 for inclusion criteria.
†ICS-only inhaler; all other patients using ICS/LABA consistent with Australian prescribing trends [37].
BDP-HFA: beclometasone dipropionate (hydrofluoroalkane propellant).
ICS: inhaled corticosteroid.
The supernatant was discarded and the cell pellet of granulo-
cytes was resuspended in sterile water for 30 seconds to lyse
remaining red blood cells before osmolarity was reestablished
with equal parts of 2x PBS. Cells were then incubated for 30
minutes at 4∘C with CD16 magnetic beads (Miltenyi Biotec,
Bergisch, Germany) before running through a magnetic
column as per the manufacturer’s instructions. Previous
optimisation of the protocol showed typical purity was 99%
or greater by a haematoxylin and eosin stain. The main
contaminating cell was eosinophils (<1%).
2.4. RV16. RV16 was generously donated by Professor Sebas-
tian Johnston, Imperial College, London, UK. RV16 was
grown in HeLa cells by standard procedures and infectivity
titre determined by a titration assay as described [33].
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2.5. Stimulation of Neutrophils with Toll-Like Receptor (TLR)
Agonists and RV16. Neutrophils were resuspended in 1%
fetal bovine serum (FBS) (Glendarach Biologicals, Mel-
bourne, Australia), 1% 1M HEPES (Gibco), and 1% peni-
cillin/streptomycin RPMI 1640 (Gibco) at 1 × 106 cells/mL.
Cells were left unstimulated (negative control) or stimulated
with EC
50
concentrations of each TLR agonist based on
dose-response curves generated for CXCL8 release (data not
shown): 1 𝜇g/mL LPS (Sigma Aldrich, St. Louis, MO, USA),
3 𝜇g/mL imiquimod (Invivogen, San Diego, USA), 1.5 𝜇g/mL
R848 (Invivogen), and 10 𝜇g/mL poly I:C (Sigma Aldrich),
except fMLF (Sigma Aldrich) (100 nM) which was based on
previous reports [34]. Neutrophils were also stimulated with
RV16 at a multiplicity of infection (MOI) of 1 infectious
particle per cell as previously published [25, 35]. Cells were
incubated at 37∘C with 5% CO
2
for 1 hour for NE and MMP-
9measurements or 24 hours for CXCL8measurements. Cell-
free supernatant and neutrophils cell pellets were collected
and stored at −80∘C for analysis.
2.6. CXCL8 Enzyme-Linked Immunosorbent Assay (ELISA).
CXCL8 production was measured using a sandwich ELISA
in duplicate. Specific ELISA kits from R&D Systems (Min-
neapolis, USA) were used according to the manufacturer’s
instructions. Detection limit was 15.6 pg/mL.
2.7. Neutrophil Elastase (NE) Activity Assay. NE activity
was measured in duplicate using a fluorescence assay from
CaymanChemicals (Ann-Arbor,USA) according to theman-
ufacturer’s instructions. Fluorescence readings from samples
were compared to a standard curve of known concentrations
of NE to determine the concentration. Detection limit was
3.1 ng/mL.
2.8. MMP-9 Zymography. A bicinchoninic acid assay (Sigma
Aldrich) was run for all samples according to the manu-
facturer’s instructions to obtain the total protein concentra-
tion. Zymography was carried out according to previously
published methods [36]. Briefly, 200 ng of total protein was
loaded into each lane of a 1% gelatin polyacrylamide gel. The
gel was run and then proteinases were activated in a CaCl
2
activation buffer overnight before staining with Coomassie
brilliant blue dye. Bands were determined to be pro-MMP-9
using size markers andMMP-9 standards. Densitometry was
performed with Carestream Molecular Imaging Software on
images taken on a Kodak Image Station from Integrated
Sciences (Chatswood, Australia) to determine the relative
fold change compared to media control.
2.9. Data and Statistical Analysis. For statistical analysis,
data was normalised (log
10
) before normality tests were
conducted (Kolmogorov-Smirnov, D’Agostino and Pearson,
and Shapiro-Wilk normality tests; GraphPad Prism 6). They
were deemed to have a normal distribution if they passed
one of the three normality tests. A paired 𝑡-test or one-way
analysis of variance (ANOVA) with Dunnett’s posttest was
performed if the data followed a normal distribution or
a Wilcoxon matched 𝑡-test or Friedman test with Dunn’s
multiple comparison test if data were nonparametric. Two-
way ANOVA with Tukey’s posttest was performed for com-
parisons between healthy controls, well-controlled asthmatic,
and suboptimally controlled asthmatic. For some data sets,
correlation analysis was performed. Significant changes were
identified where 𝑝 < 0.05.
3. Results
3.1. Patient Characteristics. Theclinical characteristics for the
study population are detailed in Tables 1 and 2. Patients were
all age and gender matched with the mean age of approx-
imately 60 years and each group consisted predominately
of males. By definition, mean ACQ was different between
the two asthma groups (good symptom control: mean 0.32,
suboptimal symptom control: mean 1.33) There were no
differences in FEV
1
% predicted between the three patient
groups; however FEV
1
/FVC% ratio was significantly less in
patients with well-controlled and suboptimally controlled
asthma compared to healthy controls (Table 1). The majority
of participants with well-controlled asthma were taking a
short-acting 𝛽
2
agonist (82%) (Table 1) with only 55% taking
an ICS containing inhaler daily (Table 2). However, all but 1
patient in this group took combination therapy intermittently
in the past 12 months (Table 2). All participants with subop-
timal asthma symptom control were taking a short-acting 𝛽
2
agonist (Table 1) along with combination therapy (Table 2).
3.2. Differential CXCL8 Release from Neutrophils from Asth-
matics. All bacterial and viralmimetics including LPS, fMLF,
imiquimod, R848, and poly I:C induced significant CXCL8
release from neutrophils isolated from healthy controls
and well-controlled and suboptimally controlled asthmatics
(Figures 1(a) and 1(b)). Interestingly, RV16 induced CXCL8
only in neutrophils from well-controlled and suboptimally
controlled asthmatics (Figure 1(c)). Neutrophils from sub-
optimally controlled asthmatics had a deficient CXCL8
response to fMLF of approximately half when compared
to healthy controls (Figure 1(a)). There was also a trend
for neutrophils derived from well-controlled asthmatics to
release less CXCL8 in response to fMLF which was of sim-
ilar magnitude to neutrophils from suboptimally controlled
asthmatics (Figure 1(a)). All other stimulants induced similar
production of CXCL8 between all three groups.
3.3. Differential NE Release fromNeutrophils from Asthmatics.
fMLF was the only pathogen mimetic to induce NE from
neutrophils in all three groups (Figure 2(a)). Interestingly,
we found that, at baseline, neutrophils from well-controlled
asthmatics had enhanced NE release compared to healthy
controls (Figure 2(a)). Furthermore, this difference was also
found when stimulated with fMLF (Figure 2(a)). RV16 did
not induce NE release from neutrophils in any of the three
groups.
3.4. Differential MMP-9 Release from Neutrophils from Asth-
matics. LPS, fMLF, and imiquimod induced MMP-9 release
from neutrophils in all three groups (Figures 3(a) and 3(b)).
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Figure 1: CXCL8 release from neutrophils stimulated with bacterial and viral mimetics and RV16. CXCL8 release from healthy controls (blue
circles, 𝑛 = 9), well-controlled asthmatic (green squares, 𝑛 = 11), and suboptimally controlled asthmatic (red triangles, 𝑛 = 7) neutrophils
stimulated with (a) bacterial compounds: lipopolysaccharide (LPS), f-Met-Leu-Phe (fMLF), andDMSO (vehicle control), (b) viral surrogates:
imiquimod, R848, and polyinosinic:polycytidylic acid (poly I:C), and (c) RV16 after 24 hours. Raw data is presented as a scatter plot with
median. ∗𝑝 < 0.05, ∗∗𝑝 < 0.01, ∗∗∗𝑝 < 0.001, and ∗∗∗∗𝑝 < 0.0001 compared to unstimulated control. #𝑝 < 0.05 between indicated groups.
Similar to CXCL8 data, fMLF stimulated neutrophils from
well-controlled and suboptimally controlled asthmatics had
a deficient MMP-9 response compared to healthy controls
(Figure 3(a)). Interestingly, R848 selectively induced MMP-
9 in neutrophils derived from well-controlled and subop-
timally controlled asthmatics, but not in healthy controls
(Figure 3(b)). RV16 did not induce MMP-9 release from
neutrophils in any of the three groups investigated.
3.5. FEV1% Predicted and FEV1/FVC% Ratio Correlated with
fMLF Induced CXCL8. To further investigate if the differ-
ences in fMLF induced CXCL8 andMMP-9 in controlled and
uncontrolled asthmatics were related to airway obstruction,
we performed correlation analysis. We found that FEV
1
%
predicted and FEV
1
/FVC% ratio positively correlated with
fMLF induced CXCL8 release (Figures 4(a) and 4(b)) but
not fMLF induced MMP-9 release (Figures 4(c) and 4(d)).
There was no correlation between ACQ and fMLF induced
CXCL8 (𝑟 = −0.318, 0.106) or MMP-9 (𝑟 = −0.181, 𝑝 =
0.367). No correlations were found between pack year history
and fMLF induced CXCL8 (𝑟 = −0.04, 𝑝 = 0.84) or basal
CXCL8 (𝑟 = −0.07, 𝑝 = 0.74). Similarly, no correlations were
found between daily ICS dose and fMLF induced CXCL8
(𝑟 = −0.15, 𝑝 = 0.45) or basal CXCL8 (𝑟 = 0.12, 𝑝 = 0.55).
We also found no correlation between basal CXCL8 release
and FEV
1
% predicted (𝑟 = 0.028, 𝑝 = 0.889) or FEV
1
/FVC%
ratio (𝑟 = 0.029, 𝑝 = 0.884).
4. Discussion
In this study we found that neutrophils from patients with
asthma respond differently to fMLF compared to healthy
controls. However, we did not see differences between neu-
trophils from patients with well- versus suboptimally con-
trolled asthma. RV16 induced CXCL8 and R848 induced
MMP-9 occurred in only neutrophils from well- and subop-
timally controlled asthmatic groups but not in neutrophils
from healthy controls. fMLF stimulation resulted in a defi-
cientMMP-9 production in neutrophils fromwell-controlled
asthmatics and a deficient CXCL8 and MMP-9 in subop-
timally controlled asthmatics. In addition, NE was differ-
entially regulated and was constitutively elevated in well-
controlled asthmatics. This increased constitutive release
most likely accounts for the difference observed in fMLF
stimulated neutrophils from well-controlled asthmatics. We
also found that fMLF induced CXCL8 and MMP-9 release
correlated with lung function but not ACQ, smoking history,
or ICS use.
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Figure 2: NE release from neutrophils stimulated with bacterial and viral mimetics and RV16. NE release from healthy controls (blue
circles, 𝑛 = 9), well-controlled asthmatic (green squares, 𝑛 = 11), and suboptimally controlled asthmatic (red triangles, 𝑛 = 7) neutrophils
stimulated with (a) bacterial compounds: lipopolysaccharide (LPS), f-Met-Leu-Phe (fMLF), andDMSO (vehicle control), (b) viral surrogates:
imiquimod, R848, and polyinosinic:polycytidylic acid (poly I:C), and (c) RV16 after 1 hour. Raw data is presented as a scatter plot withmedian.
∗
𝑝 < 0.05 compared to unstimulated control. #𝑝 < 0.05, ##𝑝 < 0.01, and ###𝑝 < 0.001 between indicated disease groups.
As airway epithelial cells and smooth muscle cells are
fundamentally altered in asthma [21–24], even when grown
for several cycles in vitro where they are deprived of altered
signals in an asthmatic airway, we hypothesised that antimi-
crobial functions would similarly be dysfunctional in neu-
trophils from suboptimally controlled asthma. We hypoth-
esised that there would be deficient immune responses
in circulating neutrophils from people with suboptimally
controlled asthma which potentially could lead to more
severe or long lasting respiratory infections and ultimately an
exacerbation.This study provides valuable and novel insights
into circulating neutrophilic inflammatory responses.
In this study we were interested in investigating if neu-
trophils are already dysfunctional prior to entering the airway
tissue in patients with asthma which could be intensified
with altered inflammatory signals. As such, we chose to use
peripheral blood neutrophils which we believe to be appro-
priate for investigation of possible differences in these cells.
Since neutrophils are released into the circulation from the
bone marrow we believe this cell population best reflects
neutrophil function that has not had further differentiation
signals provided during extravasation and in the airway
lumen.
RV is a major precipitant of viral-induced exacerbations
in asthma [8]. Neutrophils migrate into the airways during
RV infections [38, 39] but their role in antiviral immunity
remains unclear as is their ability to become infected with RV
despite expressing ICAM-1 [40], the attachment protein for
the serotype of RV used in this study. It is not clear why RV
induced CXCL8 in this study. In the absence of replication
we have previously shown that RV binding to ICAM-1 is
sufficient to induce cytokine release in some [41] but not
all lung cells [42]. Toll-like receptors (TLRs), particularly
TLR 3, TLR 7, and TLR 8, detect viruses and usually their
activation leads to typical innate activation. Potentially if
RV is phagocytosed, TLR 3, TLR 7, and TLR 8 present
on phagocytic vesicles may be activated. Alternatively cell
surface TLR 3 [43, 44] may detect the presence of the virus.
Our finding that RV16 can induce CXCL8 in asthmatic
neutrophils is novel, although the clinical relevance for the
small induction observed here is questionable and needs
to be interpreted with caution. However, the titre of RV
in vivo is likely to be much higher than we used in vitro
(reported 1000 TCID/mL in nasal lavage fluid [45]); therefore
we speculate that a greater response to RVmay occur in vivo.
It is also plausible that patients with more severe disease are
more sensitive to relatively small changes in inflammatory
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Figure 3:MMP-9 release fromneutrophils stimulatedwith bacterial and viralmimetics andRV16.MMP-9 release fromhealthy controls (blue
circles, 𝑛 = 9), well-controlled asthmatic (green squares, 𝑛 = 11), and suboptimally controlled asthmatic (red triangles, 𝑛 = 7) neutrophils
stimulated with (a) bacterial compounds: lipopolysaccharide (LPS), f-Met-Leu-Phe (fMLF), andDMSO (vehicle control), (b) viral surrogates:
imiquimod, R848, and polyinosinic:polycytidylic acid (poly I:C), and (c) RV16 after 1 hour. Raw data is presented as a scatter plot withmedian.
∗
𝑝 < 0.05, ∗∗𝑝 < 0.01, ∗∗∗𝑝 < 0.001, and ∗∗∗∗𝑝 < 0.0001 compared to unstimulated control. #𝑝 < 0.05 between indicated disease groups.
cytokine production due to the cumulative effect of a greater
number of neutrophils present. Dysregulation in CXCL8
induction by RV16 could play a role in the pathogenesis of
asthma exacerbations and persistent airway neutrophilia but
this requires further investigation.
fMLF, a bacterial derived protein and ligand for the
fMLF receptor, stimulates neutrophils to migrate, produce
inflammatory mediators, and release granules and reactive
oxygen species [46]. We observed stimulant and disease
specific changes in the response to fMLF. We believe these
changes are not related to fMLF receptor expression since in
the same patients withwell-controlled asthma; fMLF induced
CXCL8 releasewas approximately half the response of healthy
controls but NE release was augmented.
NE and MMP-9 are both proteases and are found in
neutrophil azurophil and gelatinase granules, respectively
[47]. Like all proteases, tight regulation is required to ensure
localisation of the enzymes to the area of infection; otherwise
tissue damage can occur. We observed that, even under the
same stimulation conditions, NE and MMP-9 release were
differentially regulated, that is, a deficient fMLF induced
MMP-9 response but an augmented fMLF induced NE
response in neutrophils from well-controlled asthmatics.
This differential regulation could be due to the location
of these products in different types of granules and their
differing propensity to be released from neutrophils under
certain stimulation conditions. However, further investiga-
tion of these mechanisms was outside the scope of this study
and could be the subject for future studies.
Interestingly, we found similar neutrophil responses
between patients with suboptimally controlled asthma and
well-controlled asthma, particularly with deficient fMLF
induced CXCL8 and MMP-9 release. Neutrophil function
is known to decline with age and these changes include
decreased phagocytic ability [48, 49], reduction in degranu-
lation [50], and reduced capacity to generate reactive oxygen
species [48]. In previousworkwe found that neutrophils from
asthmatics with a mean age of 35 years had a greater propen-
sity to release CXCL8 with R848 stimulation compared
to nonasthmatic controls; however, other stimulants which
included fMLF were similar between the two groups [25].
In this study where participants had a mean age of 62 years,
we did not observe enhanced R848 induced CXCL8 from
neutrophils, rather similar levels between both asthmatic
groups and healthy controls. In addition, we noted deficient
CXCL8 and MMP-9 release with fMLF stimulation which
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Figure 4: Correlation of FEV
1
and FEV
1
/FVCwith fMLF induced CXCL8 andMMP-9 from neutrophils. Correlations of fMLF induced (a-b)
CXCL8 release and (c-d) MMP-9 with FEV
1
(a-c) and FEV
1
/FVC ratio (b-d).
may suggest that decline in neutrophil function is greater in
those with disease, particularly in recognition of bacteria.
Studies have reported CXCL8 levels in the airways
inversely correlate with FEV
1
in asthmatic individuals [3, 51,
52]. These studies measured CXCL8 in the bronchial alve-
olar lavage (BAL) and induced sputum which indicate the
total inflammatory mediator load in the airways but give
little indication of the source. In this study we found that
basal CXCL8 release from neutrophils does not correlate
with lung function, suggesting that neutrophils may not be
the main source of this cytokine in BAL. However, fMLF
induced CXCL8 positively correlated with both FEV
1
and
FEV
1
/FVC. fMLF stimulates neutrophils via the FPR1 recep-
tor. Interestingly annexin A1 also activates the fMLF receptor
[53]. As corticosteroid induced annexin A1 is a major anti-
inflammatorymechanism it is interesting to speculate that the
responsiveness to fMLF may also indicate steroid insensitiv-
ity.
Our study has several limitations; the number of par-
ticipants is small and the patients with suboptimal asthma
control may have been quite heterogenous. Few participants
had an ACQ > 1.5, which is the cut point used to be confident
that asthma control is poor [30]. Aswe do not have eosinophil
counts there is potential that the suboptimally controlled
asthma group could contain steroid refractory eosinophilic
asthmatics. These patients are distinct from neutrophilic
refractory asthmatics as they have eosinophilia despite high
dose steroid therapy and respond to anti-IL-5 antibody ther-
apy [54, 55]. Detailed phenotyping and endotyping of asthma
are areas of interest to help personalise treatment options
[56]. Our study is limited in this respect and future studies
with larger population groups could address this question. It
is also becoming clear that neutrophils are a nonhomogenous
population of cells that carry out various functions ranging
from the classical proinflammatory response to an immune
modulatory response [57]. Investigation in this area was
out of the scope of our study but would be of interest to
closely investigate neutrophil subtypes in different asthmatic
populations.
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In conclusion, no significant differences were seen in
neutrophil function between patients with well- and subopti-
mally controlled asthma and therefore it is unlikely that neu-
trophil dysregulation drives asthma control. However, neu-
trophils from people with asthma appear to have different
responses to pathogenic stimuli compared to healthy con-
trols.This dysfunctionmay contribute to persistent or greater
susceptibility to infection in asthmatics and is likely to be
associated with airway obstruction.
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